Soy Protein Intake and the Metabolic Syndrome

NCT ID: NCT01694056

Last Updated: 2013-01-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-09-30

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Soy protein has a high biological value, and contains several potential health-related nutritional factors, i.e. its amino acids pattern, biological active peptides and non-protein compounds such as isoflavones. In the field of obesity and blood lipids soy protein is well-studied and appreciated; it improves circulating blood lipids and is associated with weight reduction. The effect of soy on insulin resistance, glucose homeostasis and the metabolic syndrome is less frequently studied. However, several molecular mechanisms of action of soy protein make it a promising approach.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Objective: The primary objective of the present study is to evaluate the effect of a high soy protein diet on insulin resistance and glycemic control in participants with characteristics of the metabolic syndrome. Secondly, the present study will evaluate whether reduced low-grade inflammation is a possible mechanism underlying the improvement in insulin resistance and glucose homeostasis. Finally, it will be assessed whether soy protein has beneficial effects on components of the metabolic syndrome, such as cardio-metabolic risk factors, blood lipid profile, blood pressure and endothelial function, fat storage in the liver and gene-expression in subcutaneous abdominal adipose tissue.

Study design: Single-blind, cross-over strictly-controlled dietary intervention.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Syndrome X

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Soy protein diet

High mixed protein diet (20 en%) with 25gr of soy protein per day

Group Type EXPERIMENTAL

Soy protein diet

Intervention Type OTHER

4 weeks high protein diet (20 en%) with 25gr of soy protein per day

Control diet

High mixed protein diet (20 en%)

Group Type ACTIVE_COMPARATOR

Control diet

Intervention Type OTHER

4 weeks high mixed protein diet (20 en%)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Soy protein diet

4 weeks high protein diet (20 en%) with 25gr of soy protein per day

Intervention Type OTHER

Control diet

4 weeks high mixed protein diet (20 en%)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women
* 45-70 years
* No menstrual cycle for ≥1 year
* Stable body weight for ≥6 months (no weight gain/loss \> 3 kg)
* Stable exercise habits during the last 6 months, and not participating in any vigorous exercise program
* Central obesity: waist circumference ≥80 cm

Plus any one of the following four factors:

* Raised triglyceride level: ≥1.7 mmol/L;
* Reduced high-density lipoprotein (HDL) cholesterol: \<1.29 mmol/L
* Raised blood pressure: systolic blood pressure ≥135 mmHg or diastolic BP ≥85 mmHg or use of blood pressure lowering medication
* Raised fasting plasma glucose ≥ 5.6 mmol/L

Exclusion Criteria

* (Undiagnosed) Diabetes - but not impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) as evaluated by an oral glucose tolerance test at screening
* Active hearth disease, i.e. history of myocardial infarction, stroke or angina pectoris
* Active or a history of thyroid disease
* Cancer or other malignancies in the past 5 years
* Two sided ovariectomy
* Drug use knowing to interfere with objectives of the study
* oral corticosteroids, lipid-lowering drugs (statins)
* anti-conceptive use (such as the pill or IUD)
* hormone replacement therapy
* long-term antibiotics use
* Habitual intake of soy foods (\>1 soy food per week)
* Isoflavone supplements
* Vegetarian
* Following, or have recently followed a (weight-loss) diet
* Allergic to soy or dairy products
* Smoking
* Consuming more than 14 glasses of alcohol per week
* Donated or intended to donate blood 2 months before till two months after the study
* Participation in another biomedical study within 1 month before the first screening visit
* Not willing to be informed if deviations are found in blood samples
* Contraindications to MRI scanning
Minimum Eligible Age

45 Years

Maximum Eligible Age

70 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Alpro Foundation

OTHER

Sponsor Role collaborator

Wageningen University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Marco Mensink, PhD

Role: STUDY_CHAIR

Departement of Human Nutrition, Wageningen University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Wageningen University

Wageningen, , Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

References

Explore related publications, articles, or registry entries linked to this study.

van Nielen M, Feskens EJ, Rietman A, Siebelink E, Mensink M. Partly replacing meat protein with soy protein alters insulin resistance and blood lipids in postmenopausal women with abdominal obesity. J Nutr. 2014 Sep;144(9):1423-9. doi: 10.3945/jn.114.193706. Epub 2014 Jul 9.

Reference Type DERIVED
PMID: 25008579 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NL39991.081.12

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.